Back to School: How biopharma can reboot drug development. Access exclusive analysis here
IMCL began a single-arm, open-label, U.S. Phase II trial of IV IMC-1121B
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury